Eli Lilly (LLY)

The sleeper story everyone's missing: Lilly's direct-to-consumer platform isn't just distribution innovation, it's becoming the third-largest 'PBM' in obesity with 1 million patients and one-third of all new obesity starts choosing their cash-pay vials. David Ricks nailed the framing: they've built 'a platform and an interface with consumers' that bypasses traditional healthcare friction entirely. The obvious headline is strong Q4 numbers and robust 2026 guidance, but the binding constraint is manufacturing scale-up to support what Kenneth called reaching 'tens or hundreds of millions globally' - this isn't incremental growth, it's category redefinition. Most revealing quote: 'We tend to think at a different magnitude about the opportunity here than historically what we've done with incretins.' My view changes if the Medicare pilot in July shows slower uptake than the 10-20% of current LillyDirect patients they expect to transition, or if orforglipron's ATTAIN-MAINTAIN data disappoints on weight loss maintenance versus tirzepatide.